ImmunoGen (IMGN) Short Interest Ratio & Short Volume

Short interest is the volume of ImmunoGen shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 15,580,000 shares of IMGN short. Learn More on ImmunoGen's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMGN shares currently have a short interest ratio of 2.0. Learn More on ImmunoGen's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ImmunoGen: JPMorgan Chase & Co., Susquehanna International Group LLP, Jane Street Group LLC, Belvedere Trading LLC, Group One Trading L.P., Cutler Group LLC CA, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

ImmunoGen saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 15,580,000 shares, a decrease of 32.6% from the previous total of 23,100,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to ImmunoGen: Amicus Therapeutics, Inc. (7.48%), Madrigal Pharmaceuticals, Inc. (9.01%), Geron Co. (4.54%), Alkermes plc (4.49%), Ironwood Pharmaceuticals, Inc. (10.94%), Dynavax Technologies Co. (14.38%), Ligand Pharmaceuticals Incorporated (5.03%), OPKO Health, Inc. (9.82%), MannKind Co. (14.32%), Innoviva, Inc. (13.89%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.29 billion), T-Mobile US, Inc. ($4.17 billion), Charter Communications, Inc. ($3.07 billion), Occidental Petroleum Co. ($2.81 billion), Moderna, Inc. ($2.37 billion), Coinbase Global, Inc. ($2.27 billion), T. Rowe Price Group, Inc. ($1.98 billion), Verisk Analytics, Inc. ($1.94 billion), Extra Space Storage Inc. ($1.88 billion), and Xylem Inc. ($1.61 billion). View all of the most shorted stocks.

Short selling IMGN is an investing strategy that aims to generate trading profit from ImmunoGen as its price is falling. IMGN shares are trading up $1.41 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for ImmunoGen occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IMGN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMGN, twice per month. The most recent reporting period available is May, 15 2023.